InsiderSignal.AI

InsiderSignal.ai

RAPP - Rapport Therapeutics, Inc.

Insider Sale by Ceesay Abraham (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Ceesay Abraham, serving as CEO at Rapport Therapeutics, Inc. (RAPP), sold 10,916 shares at $29.35 per share, for a total transaction value of $320,373.00. Following this transaction, Ceesay Abraham now holds 658,705 shares of RAPP.

This sale represents a 2.00% decrease in Ceesay Abraham's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, February 18, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 19, 2026, 1 day after the trade was made.

Rapport Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Ceesay Abraham

Ceesay Abraham

CEO

Abraham N. Ceesay, also known as Abe Ceesay, is the Chief Executive Officer and a Director at Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biotechnology company developing precision medicines for neurological disorders.[[1]](https://fintool.com/app/research/companies/RAPP/people/abraham-ceesay)[[2]](https://theorg.com/org/rapport-therapeutics/org-chart/abraham-abe-ceesay)[[6]](https://www.rapportrx.com/about/leadership/) Aged 47, he has held the CEO role since February 28, 2023, and joined the Board in March 2023.[[1]](https://fintool.com/app/research/companies/RAPP/people/abraham-ceesay)[[5]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/management) Ceesay earned a BS from Ithaca College and an MBA from Suffolk University’s Sawyer School of Management.[[1]](https://fintool.com/app/research/companies/RAPP/people/abraham-ceesay)[[2]](https://theorg.com/org/rapport-therapeutics/org-chart/abraham-abe-ceesay) Ceesay brings nearly two decades of biopharmaceutical experience, including prior roles as President of Cerevel Therapeutics (April 2021–March 2023), CEO of Tiburio Therapeutics (January 2019–April 2021), Chief Operating Officer at scPharmaceuticals (March 2016–October 2018), Head of Commercial at Keryx Biopharmaceuticals (February 2014–March 2016), and Vice President of Marketing at Ironwood Pharmaceuticals (July 2010–February 2014).[[1]](https://fintool.com/app/research/companies/RAPP/people/abraham-ceesay)[[2]](https://theorg.com/org/rapport-therapeutics/org-chart/abraham-abe-ceesay)[[3]](https://www.pacira.com/company/leadership/abraham-ceesay/) He currently serves on the boards of Pacira BioSciences (since October 2023), Life Science Cares (Chairman), and the Museum of Science, Boston.[[1]](https://fintool.com/app/research/companies/RAPP/people/abraham-ceesay)[[2]](https://theorg.com/org/rapport-therapeutics/org-chart/abraham-abe-ceesay) Under his leadership at Rapport, the company reported positive Phase 2a data for RAP-219 in focal onset seizures (78% reduction in frequency, 24% seizure freedom), with Phase 3 trials planned for Q2/Q3 2026.[[1]](https://fintool.com/app/research/companies/RAPP/people/abraham-ceesay)[[4]](https://www.investing.com/news/insider-trading-news/rapport-therapeutics-ceo-ceesay-sells-285k-in-shares-93CH-4461760) Ceesay recently sold 10,916 shares on January 20, 2026, for approximately $285,000 under a trading plan.[[4]](https://www.investing.com/news/insider-trading-news/rapport-therapeutics-ceo-ceesay-sells-285k-in-shares-93CH-4461760)[[8]](https://www.sahmcapital.com/news/content/rapport-therapeutics-ceo-abraham-ceesay-reports-disposal-of-common-shares-2026-01-23) His 2024 compensation was $9.84M, and he owns 1.71% of the company.[[5]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/management)

View full insider profile →

Trade Price

$29.35

Quantity

10,916

Total Value

$320,373.00

Shares Owned

658,705

Trade Date

Wednesday, February 18, 2026

4 days ago

SEC Filing Date

Thursday, February 19, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Rapport Therapeutics, Inc.

Company Overview

No company information available
View news mentioning RAPP

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4127951

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime